Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641129 | 1.00 | REN (0.77) | REN | |
| SCHEMBL4474654 | 1.00 | REN (0.77) | REN | |
| SCHEMBL4640194 | 1.00 | REN (0.77) | REN | |
| SCHEMBL4181504 | 0.95 | REN (0.70) | REN | |
| SCHEMBL377332 | 0.93 | REN (0.81) | REN | |
| SCHEMBL1596612 | 0.93 | REN (0.81) | REN | |
| SCHEMBL14098038 | 0.93 | REN (0.81) | REN | |
| SCHEMBL6044608 | 0.93 | REN (0.67) | REN | |
| SCHEMBL14098041 | 0.93 | REN (0.77) | REN | |
| SCHEMBL6044287 | 0.91 | REN (0.77) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | claimed |
| US-20120022100-A1 | ORGANIC COMPOUNDS | MAIBAUM JUERGEN KLAUS (DE) | 2012-01-26 | — | — | US | claimed |
| EP-1789377-B1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2010-10-20 | — | — | EP | claimed |
| US-7709532-B2 | Methods for improving bioavailability of a renin inhibitor | NOVARTIS AG (CH) | 2010-05-04 | — | — | US | claimed |
| EP-1776099-B1 | METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | claimed |
| EP-2094257-A1 | METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR | Novartis AG (CH) | 2009-09-02 | — | — | EP | claimed |
| US-7582782-B2 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | NOVARTIS AG (CH) | 2009-09-01 | — | — | US | claimed |
| US-20090076062-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-03-19 | — | — | US | claimed |
| EP-1978012-A1 | Alternative synthesis of renin inhibitors and intermediates thereof | Novartis AG (CH) | 2008-10-08 | — | — | EP | claimed |
| US-20080146671-A1 | MICROEMULSION PRECONCENTRATE COMPRISING A RENIN INHIBITOR | OTTINGER ISABEL | 2008-06-19 | — | — | US | claimed |
| EP-1729748-A1 | MICROEMULSION PRECONCENTRATE COMPRISING A RENIN INHIBITOR | Novartis AG (CH) | 2006-12-13 | — | — | EP | claimed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | claimed |
| WO-2006024501-A1 | ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006013094-A1 | METHODS FOR IMPROVING BIOAVAILABILITY OF A RENIN INHIBITOR | NOVARTIS AG (CH) | 2006-02-09 | — | — | WO | claimed |
| WO-2005058291-A1 | MICROEMULSION PRECONCENTRATE COMPRISING A RENIN INHIBITOR | NOVARTIS AG (CH) | 2005-06-30 | — | — | WO | claimed |
| US-20040266836-A1 | Salt of acidic AT1-receptor antagonist and basic cardiovascular ingredient; potentiation or synergism; reduction of side effects | BUHLMAYER PETER (CH) | 2004-12-30 | — | — | US | claimed |
| EP-1448190-A2 | SALTS FORMED OF AN AT1-RECEPTOR ANTAGONIST AND A CARDIOVASCULAR AGENT | Novartis AG (CH) | 2004-08-25 | — | — | EP | claimed |
| WO-2003035046-A2 | SALTS FORMED OF AN AT1-RECEPTOR ANTAGONIST AND A CARDIOVASCULAR AGENT | NOVARTIS AG (CH) | 2003-05-01 | — | — | WO | claimed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | claimed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022100-A1 | ORGANIC COMPOUNDS | AGTR1, AGTR2, REN | REN 3/4885 |
| US-20080146671-A1 | MICROEMULSION PRECONCENTRATE COMPRISING A RENIN INHIBITOR | REN, AGTR1, ACE | REN 1/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | REN 970/4885 |
| US-20040266836-A1 | Salt of acidic AT1-receptor antagonist and basic cardiovascular ingredient; potentiation or synergism; reduction of side effects | AGTR1, AGTR2, AGT | REN 4/4885 |
| US-20090076062-A1 | Organic Compounds | AGTR1, AGTR2, REN | REN 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.